R&D

News

Meet Dalton, a new AI-powered drug discovery platform

Just a few months after emerging from stealth, the UK's DaltonTx has launched its AI in drug discovery platform and revealed its first client.

News

Innovent in line for $10.5bn in Pfizer cancer alliance

Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.

News

Bristol Myers Squibb and Hengrui Pharma logos

BMS signs $15.2bn R&D alliance with China's Hengrui

Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.

R&D

12 Questions with Matthew Goodman

LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.

News

Scissors cutting a ribbon of dollars against an orange background

'Seismic shift' as obesity overtakes cancer for R&D returns

For the first time in its 16-year history, Deloitte's annual report on pharma R&D returns sees obesity replace cancer as the largest driver.

Digital

AI in clinical trials for protocol ingestion

From static documents to strategic capability: The case for ...

Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.

Meet Dalton, a new AI-powered drug discovery platform

Innovent in line for $10.5bn in Pfizer cancer alliance

BMS signs $15.2bn R&D alliance with China's Hengrui

12 Questions with Matthew Goodman

'Seismic shift' as obesity overtakes cancer for R&D returns

From static documents to strategic capability: The case for ...

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Discover a new era of healthcare panel engagement: Grounded ...

R&D

Editor's Picks